In Wednesday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $10.70, up 3.68% from the previous session.
ROIV stock price is now -3.03% away from the 50-day moving average and -5.61% away from the 200-day moving average. The market capitalization of the company currently stands at $7.63B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 100,000 shares of the company’s stock on Feb 20 ’25. The stock was sold for $1,065,000 at an average price of $10.65. Upon completion of the transaction, the President & COO now directly owns 896,869 shares in the company, valued at $9.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’25, Officer Venker Eric bought 100,000 shares of the business’s stock. A total of $1,065,022 was incurred on buying the stock at an average price of $10.65. A total of 37.95% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $9.76 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 37.91, and a quick ratio of 37.91.
The net profit margin was -119.54% and return on equity was -7.10% for ROIV. The company reported revenue of $9.02 million for the quarter, compared to $15.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.05 percent. For the current quarter, analysts expect ROIV to generate $62.17M in revenue.
